Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)

Contineum Therapeutics' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $521000.0 for Q2 2026.

• In Q2 2026, Amortization of Deferred Charges rose 129.52% year-over-year to $521000.0; the TTM figure through Jun 2026 stood at $1.8 million (up 109.12% YoY), while the FY2025 annual figure was $1.1 million, up 23.85% from the prior year.
• Amortization of Deferred Charges for Q2 2026 stood at $521000.0, down from $624000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $624000.0 in Q1 2026, with the low at $153000.0 in Q4 2024.
• The 4-year median for Amortization of Deferred Charges is $236000.0 (2023), against an average of $290142.9.
• The sharpest annual moves came in 2024 and 2026: Amortization of Deferred Charges sank 42.05% in 2024, then surged 167.81% in 2026.
• Contineum Therapeutics' Amortization of Deferred Charges stood at $264000.0 in 2023, then plunged by 42.05% to $153000.0 in 2024, then soared by 152.94% to $387000.0 in 2025, then surged by 34.63% to $521000.0 in 2026.
• Business Quant data shows CTNM's Amortization of Deferred Charges at $521000.0 in Q2 2026, $624000.0 in Q1 2026, and $387000.0 in Q4 2025.